1-6 of 6
Corinne Hoffman
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Outcomes of Patients with Chronic Lymphocytic Leukemia Discontinuing Bruton Tyrosine Kinase Inhibitors Due to Adverse Effects

Anthony G Mansour, Ying Huang, Aseel Alsouqi, Adam S Kittai, John C. Byrd, Michael R. Grever, Cecelia Miller, Gerard Lozanski, Mollie Moran, Margaret S. Lucas, Swetha Suresh, Cara Grantier, Corinne Hoffman, Mark Reid, Kerry A. Rogers, Seema A Bhat, Jennifer A. Woyach
Journal: Blood
Blood (2024) 144 (Supplement 1): 4629.
https://doi.org/10.1182/blood-2024-199676
Published: 2024
Journal Articles

Extended Follow up of a Phase 2 Study of Early Intervention with Lenalidomide in Patients with High-Risk Chronic Lymphocytic Leukemia

Kerry A Rogers, Qiuhong Zhao, Seema A Bhat, John C. Byrd, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Gerard Lozanski, Margaret S. Lucas, Lindsey Rike, Shanmugapriya Thangavadivel, William E. Carson III, Jennifer A. Woyach
Journal: Blood
Blood (2023) 142 (Supplement 1): 3272.
https://doi.org/10.1182/blood-2023-180308
Published: 2023
Journal Articles

Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study

Isaac Esplin, Ying Huang, Seema A. Bhat, Cara Grantier, Michael R. Grever, Corinne Hoffman, Adam S Kittai, Margaret S. Lucas, Mollie E. Moran, Mark Reid, Swetha Suresh, Jennifer A. Woyach, Kerry A. Rogers
Journal: Blood
Blood (2022) 140 (Supplement 1): 4166–4168.
https://doi.org/10.1182/blood-2022-167314
Published: 2022
Journal Articles

Three-Year Follow-up from a Phase 2 Study of Combination Obinutuzumab, Ibrutinib, and Venetoclax in Chronic Lymphocytic Leukemia

Kerry A. Rogers, MD, Ying Huang, MS, MA, Amy S. Ruppert, PhD, Lynne V. Abruzzo, MD PhD, Seema A Bhat, MD, Corinne Hoffman, MS, CNP, Kami J. Maddocks, MD, Gerard Lozanski, MD, Adam S. Kittai, MD, Mollie E. Moran, Mark Reid, CNP, Jennifer A. Woyach, MD, John C. Byrd, MD
Journal: Blood
Blood (2020) 136 (Supplement 1): 9–10.
https://doi.org/10.1182/blood-2020-137655
Published: 2020
Journal Articles

Brentuximab Vedotin (BV) and Lenalidomide (Len) in Relapsed and Refractory (r/r) Cutaneous (CTCL) and Peripheral (PTCL) T-Cell Lymphomas; A Planned Interim Analysis of Phase II Trial

Basem M. William, MRCP,MD, Ying Huang, MS, MA, Amy Johnson, MD, Jonathan E Brammer, MD, John C. Reneau, MD PhD, Joseph Maakaron, MD, Ruth Larbi, Cara Grantier, CNP, MPH, MS, Corinne Hoffman, MS, CNP, Sabarish Ayyappan, MBBS, Robert A Baiocchi, MD PhD, Narendranath Epperla, MDMS, Beth A. Christian, MD, Lapo Alinari, MD PhD, Kami J. Maddocks, MD, Catherine Chung, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 2853.
https://doi.org/10.1182/blood-2019-123801
Published: 2019
Journal Articles

Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia

Clinical Trials & Observations
Kerry A. Rogers, Ying Huang, Amy S. Ruppert, Farrukh T. Awan, Nyla A. Heerema, Corinne Hoffman, Gerard Lozanski, Kami J. Maddocks, Mollie E. Moran, Mark A. Reid, Margaret Lucas, Jennifer A. Woyach, W. Thomas Whitlow, Jeffrey A. Jones, John C. Byrd
Journal: Blood
Blood (2018) 132 (15): 1568–1572.
https://doi.org/10.1182/blood-2018-05-853564
Published: 2018
Includes: Supplemental data